Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA

Executive Summary

HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA April 19 to become special assistant to Deputy Commissioner for Policy Michael Taylor. Mitchell Zeller has worked as an aide to the House Government Operations/Intergovernmental Relations Subcommittee since late 1988 and is the last professional staff member who served under the late Chairman Rep. Weiss (D-N.Y.), who died last September and has been succeeded by Rep. Towns (D-N.Y.). The subcommittee was reorganized on Feb. 18 but will continue to oversee FDA operations. The new chairman is said to be interested in health care reform and in ensuring that user fee revenues are used to expedite the agency's drug approval process. However, in the wake of Weiss' death ("The Pink Sheet" Sept. 21, 1992, T&G-8) and the departure of his staff, the subcommittee is not likely to continue the kind of detailed scrutiny of FDA's scientific decisionmaking it conducted in the past. FDA issues Zeller worked on include FDA policy concessions to the Bush Administration's Council on Competitiveness, the label claims approved by FDA for the anti-arrhythmic drugs Tambocor and Enkaid, contamination problems with the nutritional supplement L- tryptophan, health claims for foods, and animal drug residues.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel